Home Cart Sign in  
Chemical Structure| 1432908-05-8 Chemical Structure| 1432908-05-8

Structure of FRAX1036
CAS No.: 1432908-05-8

Chemical Structure| 1432908-05-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FRAX-1036 is a potent and selective PAK1 inhibitor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FRAX1036

CAS No. :1432908-05-8
Formula : C28H32ClN7O
M.W : 518.05
SMILES Code : O=C1C(C2=CC=C(C3=NC(C)=CN=C3)C=C2Cl)=CC4=CN=C(NCCC5CCN(C)CC5)N=C4N1CC
MDL No. :MFCD30187513
InChI Key :RYCBSFIKWACFBY-UHFFFAOYSA-N
Pubchem ID :71557891

Safety of FRAX1036

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of FRAX1036

cytoskeleton

Isoform Comparison

Biological Activity

Target
  • PAK

    PAK4, Ki:23.3 nM

    PAK2, Ki:72.4 nM

  • PAK1

    PAK1, Ki:23.3 nM

  • PAK2

    PAK2, Ki:72.4 nM

  • PAK4

    PAK4, Ki:2.4 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
8505C >10 μM 72 hours Reduced thyroid cancer cell viability PMC7062234
Madin-Darby canine kidney cells (MDCK) 10 μM 60 minutes Evaluated permeability with Papp value of 1.2×10−6 cm/s PMC4677365
SW1736 >10 μM 72 hours Reduced thyroid cancer cell viability PMC7062234
HTh74 6.14 μM 72 hours Reduced thyroid cancer cell viability PMC7062234
BCPAP 7.73 μM 72 hours Reduced thyroid cancer cell viability PMC7062234
TPC1 3.94 μM 72 hours Reduced thyroid cancer cell viability PMC7062234
U2OS 2.5 μM FRAX1036, 0.2 μM docetaxel 20 hours To evaluate the effect of FRAX1036 and docetaxel on microtubule organization and cell fate, disorganized microtubules and increased apoptosis were observed. PMC4445529
HCC2911 5 μM FRAX1036, 0.2 μM docetaxel 24 hours To evaluate the effect of FRAX1036 and docetaxel combination on apoptosis, increased apoptotic markers (cleaved PARP) and decreased cell cycle regulators (cyclin D1) were observed. PMC4445529
THJ-16T >10 μM 72 hours Reduced thyroid cancer cell viability PMC7062234
FTC133 >10 μM 72 hours Reduced thyroid cancer cell viability PMC7062234
K1 >10 μM 72 hours Reduced thyroid cancer cell viability PMC7062234
MDA-MB-175 0.5, 1, 2.5, 5 μM 24 hours To evaluate the effect of FRAX1036 on PAK1 effector signaling and cell survival, inhibition of PAK1 effector signaling (MEK1-S298 and CRAF-S338) was observed to correlate with PARP cleavage. PMC4445529
SW480 3 μM 25 days To evaluate the effect of FRAX1036 on SW480 cell proliferation, results showed that SW480 cells regrew after 25 days of prolonged exposure to FRAX1036. PMC10539494
HCT116 1 μM 21 days To evaluate the effect of FRAX1036 on HCT116 cell proliferation, results showed that HCT116 cells regrew after 21 days of prolonged exposure to FRAX1036. PMC10539494
T47D IC50 5.0–11.5 µM 72 hours Evaluate the anti-proliferative effect of FRAX1036 in T47D cells, showing lower activity in luminal cell lines. PMC6661032
BT474 IC50 5.0–11.5 µM 72 hours Evaluate the anti-proliferative effect of FRAX1036 in BT474 cells, showing lower activity in luminal cell lines. PMC6661032
MCF7 IC50 5.0–11.5 µM 72 hours Evaluate the anti-proliferative effect of FRAX1036 in MCF7 cells, showing lower activity in luminal cell lines. PMC6661032
A549 cells 10 μM 24-48 hours To evaluate the effect of FRAX1036 on the morphology, motility, and proliferation of A549 cells. Results showed that FRAX1036 combined with prenylation inhibitors significantly altered cell morphology and motility, and reduced cell proliferation. PMC4477307
H157 cells 10 μM 24-48 hours To evaluate the effect of FRAX1036 on the morphology, motility, and proliferation of H157 cells. Results showed that FRAX1036 combined with prenylation inhibitors significantly altered cell morphology and motility, and reduced cell proliferation. PMC4477307
MS02 cells 0.6 μM, 1.2 μM, 2.5 μM, 5.0 μM 2 hours To evaluate the inhibitory effect of FRAX-1036 on PAK1 phosphorylation, results showed a profound inhibitory effect on PAK1 autophosphorylation. PMC8369838

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice MPNST subcutaneous xenograft model Oral 30 mg/kg/day Once daily for 4 weeks To evaluate the inhibitory effect of Frax1036 alone or in combination with MEK1/2 inhibitor PD-901 on MPNST xenograft growth, results showed the combination therapy significantly inhibited tumor growth PMC5608634
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice BT474 orthotopic xenografts Oral gavage 20 mg/kg daily Daily for 21 days Evaluate the anti-tumor effect of FRAX1036 in BT474 xenograft model, showing significant tumor growth inhibition when combined with alisertib. PMC6661032
Mice H292 NSCLC xenograft model Oral 10, 20, 30 mg/kg Single dose, samples collected 6 hours post-dose Assessed inhibition of pharmacodynamic biomarker pMEK S298, showing dose-dependent suppression PMC4677365
Mice Nf2 conditional knockout mouse model Oral gavage 30 mg/kg Once daily for 12 weeks To evaluate the efficacy of FRAX-1036 in slowing the growth of established schwannomas, results showed insignificant efficacy in vivo. PMC8369838

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.93mL

0.39mL

0.19mL

9.65mL

1.93mL

0.97mL

19.30mL

3.86mL

1.93mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories